Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Adjust Price Targets for Stericycle Inc Following Mixed Q4 Results

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
Finance_Assets (2)
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Following Stericycle, Inc.’s (NASDAQ: SRCL) release of its fourth-quarter financial results on February 29, 2024, analysts made changes to their forecasts and price targets for the company. The results were a mixed bag, with adjusted earnings per share coming in at 54 cents, exceeding market expectations, but quarterly sales of $652.00 million falling short.

Income from operations decreased to $37.1 million in the fourth quarter, down from $59.1 million the previous year. Stericycle’s President and CEO, Cindy J. Miller, emphasized the company’s progress in achieving key business priorities in 2023, such as enhancing efficiency and optimizing the portfolio.

In response to the quarterly results, several analysts adjusted their price targets for Stericycle:
– Truist Securities raised the price target to $57 from $50, maintaining a Hold rating.
– Stifel increased the price target to $75 from $70, with a Buy rating.
– RBC Capital raised the price target to $69 from $58, with an Outperform rating.

Despite these changes, the average one-year price target for Stericycle stands at approximately $54.50, with forecasts ranging from $40.4 to $73.5. On February 29th, the stock was trading at $55.65 per share, above the average analyst 12-month target price of $54.50.

Stericycle Inc. (SRCL) Stock Price Drops Slightly on February 29, 2024 – Analysis and Overview

On February 29, 2024, Stericycle Inc. (SRCL) experienced a slight drop in its stock price, closing at $55.69. Despite this decrease, the company is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating overall strength in the stock.

SRCL opened at $57.06, which was $1.41 higher than its previous close. However, throughout the day, the stock saw a decrease of $1.37, resulting in a 2.47% drop by the time the market closed. This fluctuation in price could be attributed to various factors such as market conditions, industry trends, or company-specific news.

SRCL Stock Performance Analysis: Strong Improvements in Net Income and EPS Despite Flat Revenue Growth

On February 29, 2024, SRCL stock had a mixed performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was $2.70 billion, which remained flat compared to the previous year. Similarly, the total revenue for the third quarter of the year was $653.50 million, also showing no growth compared to the previous quarter.

However, despite the stagnant revenue growth, SRCL showed significant improvement in its net income. The net income for the past year was $56.00 million, marking a 301.44% increase compared to the previous year. In the third quarter, the net income was $2.00 million, showing a 104.04% increase compared to the previous quarter.

Furthermore, the earnings per share (EPS) also saw a positive trend for SRCL. The EPS for the past year was $0.61, reflecting a 300.17% increase compared to the previous year. In the third quarter, the EPS was $0.02, showing a 104.02% increase compared to the previous quarter.

Overall, despite the flat revenue growth, SRCL demonstrated strong improvements in its net income and earnings per share. Investors may view these positive financial indicators as a sign of a potentially promising future for the company. However, it is important to conduct further research and analysis before making any investment decisions based on this information.

Tags: SRCL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Revolutionizing Cancer Treatment The Rise of LAVA Therapeutics NV

Acknowledgement of Minimum Postage Value

Biotechnology Markets and money

Advancements and Collaborations Propelling LAVA Therapeutics NV into the Future

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com